Small molecule · Antagonist of T-type calcium channel · developed by NEUROCRINE BIOSCIENCES
NBI-827104 is a T-type calcium channel blocker studied in epileptic encephalopathy and continuous spike and wave during sleep.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05301894 | Phase 2 | Epileptic Encephalopathy | Terminated | NBIX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Continuous Spike and Wave During SleepEpileptic Encephalopathy
Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.
See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NBIX catalysts and pipeline →